Associated Papers
Impact of low BMI and ABCC2 genotype on the clinical response of sequential anthracycline-taxane chemotherapy receiving breast cancer patients: a hospital-based study.
Mistry T et al.
The Pharmacogenomics Journal, 2025
Association Between ABCC2 -24C>T and Nab-Paclitaxel-induced Peripheral Neuropathy in Japanese Patients With Pancreatic Cancer.
Nakayama H et al.
Anticancer Research, 2024
Association between genetic variants of transmembrane transporters and susceptibility to anthracycline-induced cardiotoxicity: Current understanding and existing evidence.
Ni MM et al.
Clinical Genetics, 2024
Retention of indoxyl sulfate in different genotypes of ABCC2 may explain variation in tacrolimus pharmacokinetics.
Wang J et al.
Peerj, 2024
Drug transporters are implicated in the diffusion of tacrolimus into the T lymphocyte in kidney and liver transplant recipients: Genetic, mRNA, protein expression, and functionality.
Coste G et al.
Drug Metabolism and Pharmacokinetics, 2022
Atorvastatin population pharmacokinetics in a real-life setting: Influence of genetic polymorphisms and association with clinical response.
Stillemans G et al.
Clinical and Translational Science, 2022
Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge.
Lavacchi D et al.
Pharmacology & Therapeutics, 2022
Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites.
Liu Z et al.
European Journal of Clinical Pharmacology, 2022
Associations Between Genetic Polymorphisms Within Transporter Genes and Clinical Response to Methotrexate in Chinese Rheumatoid Arthritis Patients: A Pilot Study.
Cen H et al.
Pharmacogenomics and Personalized Medicine, 2022
ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients.
Patil A et al.
Cancer Medicine, 2021
ABC transporter superfamily. An updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine.
Juan-Carlos PM et al.
Molecular Biology Reports, 2021
Effects of AQP4 and KCNJ10 Gene Polymorphisms on Drug Resistance and Seizure Susceptibility in Chinese Han Patients with Focal Epilepsy.
Zhu H et al.
Neuropsychiatric Disease and Treatment, 2020
ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.
Riera P et al.
Frontiers in Pharmacology, 2020
Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium.
Yee SW et al.
Clinical Pharmacology and Therapeutics, 2018
The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.
Cliff J et al.
Critical Reviews in Oncology/hematology, 2017
Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.
Rodieux F et al.
Journal of Clinical Pharmacology, 2016
Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?
Alfonsi JE et al.
Current Atherosclerosis Reports, 2016
Genetic and/or non-genetic causes for inter-individual and inter-cellular variability in transporter protein expression: implications for understanding drug efficacy and toxicity.
Koo SH et al.
Expert Opinion on Drug Metabolism & Toxicology, 2015
[Single nucleotide polymorphisms in lung cancer patients and cisplatin treatment].
Stenzel-Bembenek A et al.
Postepy Higieny I Medycyny Doswiadczalnej (online), 2014
Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
Dulucq S et al.
Expert Opinion on Drug Metabolism & Toxicology, 2014
Genotype variability and haplotype profile of ABCB1 (MDR1) gene polymorphisms in Macedonian population.
Naumovska Z et al.
Prilozi (makedonska Akademija Na Naukite I Umetnostite. Oddelenie Za Medicinski Nauki), 2014
Fetal polymorphisms at the ABCB1-transporter gene locus are associated with susceptibility to non-syndromic oral cleft malformations.
Omoumi A et al.
European Journal of Human Genetics : Ejhg, 2013
Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.
Kiyotani K et al.
Journal of Human Genetics, 2013
Linkage disequilibrium between polymorphisms of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex partial seizures on treatment with carbamazepine mono-therapy at the Kuala Lumpur Hospital.
Subenthiran S et al.
Plos One, 2013
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer.
Paulík A et al.
Acta Medica (hradec Kralove), 2012
Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.
Cecchin E et al.
The Pharmacogenomics Journal, 2011
The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Chew SC et al.
Cancer Chemotherapy and Pharmacology, 2011
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy.
Sadee W et al.
Clinical Pharmacology and Therapeutics, 2011
Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
Akamine Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2010
Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients.
Grover S et al.
Biochimie, 2010
Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects.
Cho HY et al.
Neuroscience, 2010
Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.
Rocha V et al.
Leukemia, 2009
Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy.
Kim DW et al.
Epilepsy Research, 2009
Silent (synonymous) SNPs: should we care about them?
Hunt R et al.
Methods in Molecular Biology (clifton, N.j.), 2009
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
Johnatty SE et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2008
Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials.
Seedhouse CH et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2007
Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
Miura M et al.
European Journal of Clinical Pharmacology, 2007
Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation.
Ng FL et al.
Expert Opinion on Pharmacotherapy, 2007
Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.
Haenisch S et al.
The Pharmacogenomics Journal, 2007
Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.
Izzedine H et al.
The Journal of Infectious Diseases, 2006
Analyses of single nucleotide polymorphisms and haplotype linkage of the human ABCB1 (MDR1) gene in Korean.
Ryu HC et al.
Archives of Pharmacal Research, 2006
Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy.
Ieiri I et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer.
Komoto C et al.
Drug Metabolism and Pharmacokinetics, 2006
Implications of genetic polymorphisms in drug transporters for pharmacotherapy.
Kerb R
Cancer Letters, 2006
mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
Gréen H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006
Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition.
Dey S
Expert Opinion on Drug Delivery, 2006
Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
Bosch TM et al.
Molecular Diagnosis & Therapy, 2006
MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males.
Zhang WX et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2005
[Polymorphisms of the multiple drug resistance gene (MDR1) in Mapuche, Mestizo and Maori populations in Chile].
Wielandt AM et al.
Revista Medica De Chile, 2004